Life Sciences & Biotechnology
Title : | To study the role of KDM5D (Lysine Demethylase 5D) gene expression in migration and invasion of oral cancer cells |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Manish Kumar, All India Institute Of Medical Sciences (AIIMS), Bilaspur, Himachal Pradesh |
Timeline Start Year : | 2023 |
Timeline End Year : | 2026 |
Contact info : | kumar.aiims23@gmail.com |
Equipments : | -20`C Deep Refrigerator |
Details
Executive Summary : | Oral Squamous Cell Carcinomas (OSCCs) are the sixth most common cancer, causing 300,000 deaths annually worldwide. Despite advances in treatments, survival rates have not improved in 30 years. Therapeutic resistance in OSCC patients is generally related to malignancies becoming more aggressive. The Y chromosome is vital for biological processes, and the deletion of the Y-chromosome-linked gene KDM5D (Lysine Demethylase 5D) is associated with poor OSCC survival. The role of KDM5D in oral cancer, EMT, and therapy is unknown. Understanding how changes in KDM5D expression affect OSCC invasiveness would improve our understanding and provide therapeutic alternatives. The study aims to examine the clinical significance of KDM5D in oral premalignant tissues, oral cancer tissues, and normal oral tissues, as well as its role in oral cancer cell migration and invasion. Experiments will involve immunohistochemical analysis for KDM5D and MMP proteins proteins, establishing stable KDM5D expressing oral cancer cell lines, examining phenotypic changes in cells in the context of KDM5D expression, and determining the effect of KDM5D on oral cancer progression. The research will also validate the expression of Ki67, VEGF, Cyclin D, MMPs, and other MMPs in oral cancer cells. Completion of this research will provide insights into the clinical significance of KDM5D in oral cancer patients, its role in OSCC progression, the potential loss of KDM5D expression leading to EMT, and whether it drives oral cancer cell invasion. This research could help establish a novel epigenetic class of drugs in existing therapy regimens for OSCC patients. |
Total Budget (INR): | 36,66,168 |
Organizations involved